Mr Devalia is a fully accredited breast and oncoplastic surgeon and is on the GMC's Specialist Register. his papers on clinical management of breast cancer and techniques, have been published in several medical journals.
He commenced his higher surgical training in Oxford Deanery and continued as a specialist registrar in the London Deanery. he trained at various hospitals including St. Georges Hospital (London), Ashford & St.Peter's Hospital (Chertsey), the Royal Surrey County hospital (Guildford), and worked as a senior registrar in the oncoplastic breast unit at the Royal Marsden Hospital (Sutton).
After the completion of his training, he was appointed as a Locum Consultant at the Royal Marsden Hospital before his substantive appointment at Maidstone and Tunbridge Wells NHS Trust as the 'Consultant breast and oncoplastic surgeon'.
Mr Devalia was certified as 'Best student at National Level in General Surgery' (August 1997) and was awarded a Gold Medal in the final examination for the Diploma of National Board, India.
Mr Devalia specializes in the following procedures at Nuffield Health Hospital Tunbridge Wells:
- Weekly Monday AM
- Consultant Breast and Oncoplastic Surgeon, Maidstone and Tunbridge Wells Hospital
- Breast cancer lead and MDT Chair
Mr Devalia's main clinical interests lie in the field of breast surgery including the early detection of breast cancer, minimal, access breast surgery, the sentinel node biospy, skin-sparing mastectomy and immediate breast reconstruction, delayed reconstruction, breast enlargement, breast reduction, mastopexy and nipple reconstruction. He also performs breast lipomodelling (fat transfer).
Golf and swimming.
- British Medical Association
- Royal College of Surgeons (Ed)
- British Association of Surgical Oncologists
Mr Devalia has published in various peer-reviewed and international literatures. He carries out his research at London Research Institute on oncological safety of preserving the skin envelope in patients undergoing mastectomy and immedicate breast reconstruction for breast cancer. It was subsequently evaluated by a prospective patient survey which showed extremely high statisfaction.